Argenx (ARGX) said late Tuesday its Vyvgart drug resulted in "significant improvement" in muscle strength and physical function in phase 2 studies evaluating three myositis subtypes.
The company also said the US Food and Drug Administration has granted the drug, also called efgartigimod, fast-track designation for the treatment of primary Sjogren's disease.
Sjogren's disease and myositis are inflammatory autoimmune diseases that can have a material negative impact on a patient's quality of life.
In a phase 2 proof-of-concept study, 45.5% of Sjogren's patients treated with efgartigimod showed improved outcomes compared with just 11.1% for the placebo group, Argenx said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.